Menu
DRUG GUIDE

Real Talk Rx: Idvynso™

Your guide to Idvynso for the treatment of HIV
Brand Name: Idvynso
Generic Name: doravirine and islatravir
Drug Class: Complete two-drug, once-daily oral tablet — Non-nucleoside reverse transcriptase inhibitor, plus a nucleoside analog reverse transcriptase inhibitor (NNRTI + NRTI)

Idvynso is a complete HIV treatment regimen in a once-a-day tablet. Combining the long-studied doravirine with islatravir, a newer NRTI, it attacks the virus in multiple ways. Idvynso is made by Merck and was FDA-approved in April 2026. Idvynso is the first tenofovir-free, non-integrase-inhibitor, once-daily two-drug tablet shown to work as well as Biktarvy in clinical trials. Idvynso does not cure HIV and is meant to replace an existing viral suppression regimen.

Who Can Take Idvynso?

Idvynso may be prescribed for the treatment of HIV in:

  • Adults 18 and over
  • People whose virus is currently undetectable on a stable regimen
  • People with no known resistance to doravirine

Idvynso is not for people taking a strong CYP3A enzyme inducer, or lamivudine or emtricitabine.

How Does Idvynso Work?

Doravirine, the NNRTI in Idvynso, blocks reverse transcriptase, the enzyme HIV uses to convert its genetic material into a form your cells can copy. Without that step, the virus can’t make new copies of itself.

Islatravir is a newer NRTI that works differently from older ones. Instead of simply stopping the copying process, it jams reverse transcriptase so the enzyme can’t move along the viral genetic material, and it also disrupts the copy itself. This dual action is something older NRTIs don’t have. 

How Is Idvynso Taken?

Idvynso (100 mg of doravirine and 0.25 mg of islatravir) is to be taken once a day in one tablet, with or without food.

If you take rifabutin alongside Idvynso, your provider will want you to take a separate 100 mg tablet of doravirine about 12 hours after your Idvynso dose as part of your rifabutin regimen. Never take two doses of Idvynso at once.

What Does the Research Show?

Idvynso’s FDA approval was built on the results of two phase 3 active-controlled, non-inferiority clinical trials in adults whose virus was already suppressed. Across both trials, 708 people received Idvynso, and 38 percent identified as Black or African American.

Trial 052 was a double-blind study of 342 people who switched from Biktarvy to Idvynso and 171 people remained on Biktarvy. At 48 weeks, both sets maintained undetectable status at 92 and 94 percent, respectively, showing that the two regimens worked nearly equally well.

Trial 051 was an open-label study of 366 people who switched to Idvynso from a variety of regimens, and 185 people remained on their existing regimens. At 48 weeks, both sets maintained undetectable status at 96 and 92 percent, respectively. The results were consistent across age, sex, and race in both trials.

Weight change was mixed across both trials. Those in Trial 052 saw essentially no change in weight (-0.03 kg) when switching to Idvynso and gained some weight on Biktarvy (+0.28 kg). However, in Trial 051, those who switched to Idvynso saw some weight gain (+0.94 kg) compared to those who stayed on their existing regimen (-0.15 kg). It is important to note that several of the people who switched to Idvynso were previously on regimens containing efavirenz or tenofovir disoproxil fumarate, which are both associated with weight loss.  

Common Side Effects of Idvynso

Possible side effects include:

  • Diarrhea
  • Dizziness
  • Fatigue
  • Bloating
  • Headache
  • Weight changes

Serious Side Effects of Idvynso

Discontinue Idvynso immediately and seek medical treatment right away for: 

  • Signs or symptoms of severe skin reaction
  • A painful rash with fever, blistering, swelling of the face or tongue, or trouble breathing
  • Signs of an allergic reaction
  • Fever, swollen glands, or an old infection flaring up as your immune system recovers (immune reconstitution syndrome)

Special Precautions 

It is worth noting that Idvynso does not treat hepatitis B. If you have both HIV and hepatitis B, switching to Idvynso from a regimen that was also controlling your hepatitis B means you will likely need a separate medication for it. Tell your doctor if you have or have ever had hepatitis B. 

The importance of staying on schedule

Do not miss or skip doses of Idvynso. This raises your risk of building resistance to the medication. Take it at the same time every day and avoid running out of it.

What Should You Discuss With Your Doctor?

Idvynso is not to be combined with a strong CYP3A enzyme inducer, or lamivudine or emtricitabine. If you have taken rifabutin in the past four weeks before starting Idvynso, tell your doctor. Always tell your doctor about every medication and supplement you take so they can check for these interactions before you start Idvynso.

Tell your healthcare provider if you have:

  • Any history of allergic or skin reactions to HIV medicines
  • All medications you take, including rifabutin, and any strong CYP3A-inducing drugs
  • Plans to become pregnant, or if you are pregnant or breastfeeding

Why This Matters for Black Patients

Black people tend to be hit the hardest with HIV, making up 39 percent of new HIV diagnoses in 2024, despite being only 12 percent of the U.S. population. Black people with HIV are also among the least likely of any race to receive medical care within a month of diagnosis. Gaps in treatment can stem from insurance coverage, transportation, housing instability, provider bias, and medical mistrust.

Idvynso is still a new HIV regimen, only approved in April 2026, so it hasn’t built up the same amount of data that other HIV regimens may have, especially for Black patients. However, the trials that have been performed for Idvynso have had higher representation of Black patients compared to many HIV trials of the past. Black or African American patients made up between 31 and 45 percent of the two trials’ populations and treatment results were consistent across race, sex, and age groups.

If you’re worried about weight gain on an HIV regimen, Idvynso is not an integrase inhibitor (INSTI), nor does it contain tenofovir alafenamide, which tends to be associated with higher weight gain in Black patients and women. If you’ve experienced weight gain on INSTI-based regimens like dolutegravir or bictegravir, Idvynso could be a better option. Don’t be afraid to ask your provider about your options if weight gain is a concern.

What Savings and Support Programs are Available?

Merck offers copay assistance through the Merck Access Program that may bring your out-of-pocket cost for Idvynso to as low as $0 per prescription if you have commercial insurance. Call 1-877-709-4455 or visit merckaccessprogram-IDVYNSO.com for more information about eligibility.

Merck also works with the ADAP Crisis Task Force to help provide Idvynso to eligible populations. Every state has an AIDS Drug Assistance Program (ADAP) that helps cover HIV medication costs for those who are uninsured or underinsured and meet certain income limits.

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking any drug or commencing or discontinuing any course of treatment.

References
  1. Merck. FDA Approves Merck's Once-Daily IDVYNSO™ (doravirine/islatravir). Press release, April 21, 2026. https://www.merck.com/news/fda-approves-mercks-once-daily-idvynso-doravirine-islatravir/ 
  2. IDVYNSO™ (doravirine/islatravir). Official Healthcare Professional Site. Merck. https://www.merckconnect.com/idvynso/ 
  3. Same as reference 2 — full prescribing information, adverse reaction tables, and safety data. https://www.merckconnect.com/idvynso/ 
  4. Centers for Disease Control and Prevention. HIV Diagnoses, Deaths, and Prevalence: 2026 Update.  https://www.cdc.gov/hiv-data/nhss/hiv-diagnoses-deaths-and-prevalence-2026.html 
  5. Centers for Disease Control and Prevention. National HIV Prevention and Care Objectives: 2026 Update and Social Determinants of Health, HIV Diagnoses, and Selected Care Outcomes: 2025 Update. https://www.cdc.gov/hiv-data/nhss/national-hiv-prevention-and-care-objectives-2026.html 
  6. Weight Gain on Contemporary Integrase Strand Transfer Inhibitors and Tenofovir Alafenamide in Persons With HIV Starting Antiretroviral Therapy in the United States and Canada. Journal of Infectious Diseases, 2026. https://doi.org/10.1093/infdis/jiag271 
  7. Merck. Patient Support Programs / Merck Access Program for IDVYNSO. https://www.merck.com/patients/patient-support-programs/ 
  8. National Alliance of State and Territorial AIDS Directors (NASTAD). ADAP Crisis Task Force Fact Sheet. https://nastad.org/resources/adap-crisis-task-force-fact-sheet 
  9. Centers for Disease Control and Prevention. HIV Basics: Undetectable = Untransmittable (U=U). https://www.cdc.gov/global-hiv-tb/php/our-approach/undetectable-untransmittable.html

Frequently Asked Questions

More from this guide

Answer the question below
What resources do you need the most as a caregiver?

Where Culture Meets Care

BlackDoctor is the world’s largest and most comprehensive online health resource specifically for the Black community. BlackDoctor understands that the uniqueness of Black culture - our heritage and our traditions - plays a role in our health. BlackDoctor gives you access to innovative new approaches to the health information you need in everyday language so you can break through the disparities, gain control and live your life to its fullest.
✦ AI Search Disclaimer
This AI-powered search tool helps you find relevant health articles from the BlackDoctor.org archive. Please keep the following in mind:
✦ For Informational Purposes Only
The information provided through this AI search is for general educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment.
✦ Always Consult a Healthcare Provider
Never disregard professional medical advice or delay seeking it because of something you have read through this search tool. If you have a medical emergency, call your doctor or 911 immediately.
✦ AI Limitations
This search tool uses artificial intelligence to help match your queries with articles in our archive. While we strive for accuracy, AI-generated results may occasionally be incomplete, outdated, or not fully relevant to your specific situation.
✦ No Doctor-Patient Relationship
Using this search tool does not create a doctor-patient relationship between you and BlackDoctor.org or any healthcare provider.
Explore over 35,000 articles and videos across black health, wellness, lifestyle and culture
Full AI Search Experience >